Misplaced Pages

Norelgestromin/ethinylestradiol

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Redirected from Ortho Evera) Pharmaceutical combination

Pharmaceutical compound
Norelgestromin/ethinylestradiol
Combination of
NorelgestrominProgestogen
EthinylestradiolEstrogen
Clinical data
Trade namesOrtho Evra, Xulane, Evra, others
AHFS/Drugs.comProfessional Drug Facts
MedlinePlusa602006
License data
Pregnancy
category
  • Contraindicated
Routes of
administration
Transdermal (patch)
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
  • None
UNII
KEGG
Chemical and physical data
FormulaC41H53NO4
Molar mass623.878 g·mol
3D model (JSmol)
SMILES
  • CCC12CCC3C(C1CCC2(C#C)O)CCC4=CC(=NO)CCC34.CC12CCC3C(C1CCC2(C#C)O)CCC4=C3C=CC(=C4)O
InChI
  • InChI=1S/C21H29NO2.C20H24O2/c1-3-20-11-9-17-16-8-6-15(22-24)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2;1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h2,13,16-19,23-24H,3,5-12H2,1H3;1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/b22-15-;/t16-,17+,18+,19-,20-,21-;16-,17-,18+,19+,20+/m01/s1
  • Key:KBFRRZPPJPKFHQ-WKXKRCMPSA-N

Norelgestromin/ethinylestradiol, sold under the brand name Ortho Evra among others, is a contraceptive patch containing the progestin norelgestromin and the estrogen ethinylestradiol.

The most common side effects include headache, nausea (feeling sick), breast tenderness, and irregular uterine bleeding.

Norelgestromin/ethinylestradiol is a transdermal patch (a patch that delivers a medicine across the skin). For the first three weeks of the menstrual cycle a new patch should be applied every week, followed by a fourth week, which is patch-free. The patch-free interval must not be longer than seven days; otherwise, additional non-hormonal contraceptive methods must be used, such as condoms. Transdermal patches must always be applied on the same day of the week to the buttock, abdomen (belly), upper arm or upper back. The same area of skin should not be used for two consecutive patches. Norelgestromin/ethinylestradiol may work less well in women weighing 198 pounds (90 kg) or more.

Norelgestromin/ethinylestradiol was approved for medical use in the United States in November 2001, and in the European Union in August 2002. It is available as a generic medication.

Medical uses

In the United States norelgestromin/ethinylestradiol is indicated for the prevention of pregnancy in women with a BMI < 30 kg/m for whom a transdermal delivery system is an appropriate method of contraception.

In the European Union, norelgestromin/ethinylestradiol is indicated for use as female contraception.

See also

References

  1. "Evra Product information". Health Canada. 21 June 2018. Retrieved 17 February 2020.
  2. "Evra transdermal patch - Summary of Product Characteristics (SmPC)". (emc). 26 June 2020. Archived from the original on 24 October 2020. Retrieved 4 July 2020.
  3. "Ortho Evra (norelgestromin/ethinyl estradiol transdermal system) Initial U.S. Approval: 2001". DailyMed. 12 July 2018. Retrieved 4 July 2020.
  4. ^ "Xulane- norelgestromin and ethinyl estradiol patch". DailyMed. 7 April 2020. Retrieved 4 July 2020.
  5. "Ortho Evra: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 4 July 2020.
  6. ^ "Evra EPAR". European Medicines Agency (EMA). 5 August 2008. Retrieved 4 July 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  7. Graziottin A (2006). "A review of transdermal hormonal contraception : focus on the ethinylestradiol/norelgestromin contraceptive patch". Treatments in Endocrinology. 5 (6): 359–65. doi:10.2165/00024677-200605060-00004. PMID 17107221. S2CID 21033630.
  8. "Drug Approval Package: Ortho EVRA (Norelgestromin/Ethinyl Estradiol Transdermal System NDA #21-180". U.S. Food and Drug Administration (FDA). Retrieved 4 July 2020.
  9. "Xulane (Norelgestromin and Ethinyl Estradiol Transdermal System), 150 mcg/35 mcg per day" (PDF). Abbreviated New Drug Application. U.S. Food and Drug Administration. 16 April 2014.
Birth control methods
Related topics
Long-acting reversible
contraception
(LARC)
Sterilization
Hormonal contraception
Combined
estrogen–progestogen
Progestogen-only
SERMs
Barrier Methods
Emergency Contraception
(Post-intercourse)
Spermicides
Behavioral
Including
vaginal intercourse
Avoiding
vaginal intercourse
Experimental
Active molecules in hormonal contraceptives
Androgens
Estrogens
Progestogens
First generation (estranes)
Second generation
Third generation (gonanes)
Fourth generation
Pregnanes
Miscellaneous
Estrogen receptor modulators
ERTooltip Estrogen receptor
Agonists
Mixed
(SERMsTooltip Selective estrogen receptor modulators)
Antagonists
  • Coregulator-binding modulators: ERX-11
GPERTooltip G protein-coupled estrogen receptor
Agonists
Antagonists
Unknown
See also
Receptor/signaling modulators
Estrogens and antiestrogens
Androgen receptor modulators
Progesterone receptor modulators
List of estrogens
Progesterone receptor modulators
PRTooltip Progesterone receptor
Agonists
Mixed
(SPRMsTooltip Selective progesterone receptor modulators)
Antagonists
mPRTooltip Membrane progesterone receptor
(PAQRTooltip Progestin and adipoQ receptor)
Agonists
Antagonists
See also
Receptor/signaling modulators
Progestogens and antiprogestogens
Androgen receptor modulators
Estrogen receptor modulators
List of progestogens
Portal:


Stub icon

This drug article relating to the genito-urinary system is a stub. You can help Misplaced Pages by expanding it.

Categories:
Ad.

Before you begin

Life Coaching By Dr. Ann
Or continue to this article
X